骨转移瘤异质性作为雌激素受体阳性乳腺癌患者的重要预后因素:[18F]氟雌二醇PET/CT与[18F]氟脱氧葡萄糖PET/CT联合应用的作用
本研究纳入49例新诊断骨转移且拟接受一线全身内分泌治疗的雌激素受体阳性转移性乳腺癌患者,治疗前行[18F]FES PET/CT与[18F]FDG PET/CT基线检查,半定量评估全身骨代谢负荷以评价疾病范围、肿瘤代谢与ER异质性。中位随访44.7个月,35例(71.4%)疾病进展、15例(30.6%)死于疾病;Cox模型显示仅[18F]FDG全身骨代谢负荷与PFS独立直接相关(p=0.02),仅FES/FDG全身骨代谢负荷比值与OS相关(p=0.01)。结论认为两法联合可识别乳腺癌骨转移的ER异质性,该异质性与生存显著相关,FDG高摄取成分的范围与疾病进展风险相关。
要点
- 联合[18F]FES与[18F]FDG PET/CT可显示乳腺癌骨转移灶的ER异质性。
- 仅[18F]FDG全身骨代谢负荷与PFS独立直接相关(p=0.02)。
- 仅FES/FDG全身骨代谢负荷比值与OS相关(p=0.01)。
核心结论
- 联合[18F]FES-PET/CT与[18F]FDG-PET/CT可识别乳腺癌骨转移中的ER异质性,该异质性与生存显著相关,且FDG高摄取成分的范围与疾病进展风险相关。
研究设计与样本
- 研究纳入新诊断骨转移、拟接受一线全身内分泌治疗的雌激素受体阳性转移性乳腺癌患者,治疗前行基线[18F]FES PET/CT与[18F]FDG PET/CT,对全身骨代谢负荷进行半定量评估,采用Kaplan-Meier与Cox比例风险模型进行时间-事件分析以评估PFS与OS,共纳入49例患者。
诊断标准与关键数值
- 中位随访44.7个月,35例(71.4%)疾病进展、15例(30.6%)死于疾病;Cox模型中仅[18F]FDG全身骨代谢负荷与PFS独立直接相关(p=0.02),仅FES/FDG全身骨代谢负荷比值与OS相关(p=0.01)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To assess the prognostic role of different inter and intralesional expression (heterogeneity) of oestrogen receptor (ER) in bone metastases, as identified by the combined use of [18F]FES PET/CT and [18F]FDG PET/CT in patients with oestrogen receptor-positive (ER+) metastatic breast cancer (BC).
METHODS: We analysed patients with a new diagnosis of bone metastases who were candidates for first-line systemic endocrine therapy. Before starting therapy, patients underwent baseline [18F]FES PET/CT and [18]FDG PET/CT. Semi-quantitative evaluation of whole-body bone metabolic burden (WB-B-MB) was performed on [18F]FES and [18F]FDG PET/CT in order to evaluate disease extent, tumour metabolism and ER heterogeneity. We used time-to-event analyses (Kaplan-Meier and Cox proportional-hazards methods) to estimate progression-free (PFS) and overall survival (OS), in order to assess the independent prognostic value of [18F]FES PET/CT and [18F]FDG PET/CT, alone and in combination.
RESULTS: According to our criteria, we enrolled 49 patients. Over a median follow-up of 44.7 months, 35 patients suffered disease progression (71.4 %) and 15 died of disease (30.6 %). When the risk of disease progression was calculated by means of the Cox model, only [18F]FDG WB-B-MB was independently and directly associated to PFS (p = 0.02). On analysing the association between all prognostic parameters and survival, the Cox model showed that the only parameter associated with OS was the WB-B-MB FES/FDG ratio (p = 0.01).
CONCLUSION: The combined use of [18F]FES-PET/CT and [18F]FDG-PET/CT can identify ER heterogeneity in BC bone metastases. This heterogeneity is significantly associated with survival. Moreover, the extension of the FDG-avid component correlates with the risk of disease progression.
引用
- Bottoni G, Piccardo A, Fiz F, et al. Heterogeneity of bone metastases as an important prognostic factor in patients affected by oestrogen receptor-positive breast cancer. The role of combined [18F]Fluoroestradiol PET/CT and [18F]Fluorodeoxyglucose PET/CT. Eur J Radiol. 2021. PMID: 34139575. doi:10.1016/j.ejrad.2021.109821
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。